



ASX Announcement

Capital Structure and Restricted Securities

Sydney, Australia

Nyrada Inc. (ASX: NYR, 'Nyrada' or 'Company') is pleased to announce the following:

Capital Structure

The capital structure of the Company as at 13 January 2020 is as follows:

| Security type* | Number |
|--|--------------------|
| CDIs | 109,383,722 |
| Shares of Performance Common Stock | 18,000,000 |
| Options with an exercise price of AU\$0.20 and an exercise period ending on 30 November 2020 (CN Options) | 1,725,656 |
| ESOP Options | 31,500,000 |
| Warrants | 8,000,000 |
| Total – Fully diluted securities | 168,609,378 |

*The terms and conditions of these securities are set out in the prospectus dated 26 November 2019 (as varied by the supplementary prospectus dated 9 December 2019) and the Company's pre-quotation disclosure.

Restricted Securities

The number of Nyrada's securities subject to ASX restrictions and the restriction period applied to those securities as at 13 January 2020 is as follows:

| Period of Restriction | Securities |
|---|---|
| 24 months from admission to the Official List of ASX | 33,105,853 CDIs 18,000,000 Shares of Performance Common Stock 29,600,000 ESOP Options 1,030,457 CN Options 8,000,000 Warrants |
| 12 months from issue of security From 25 November 2019; and From 9 January 2020 | 205,000 CDIs 695,199 CN Options |
| Unrestricted | 76,072,869 CDIs 1,900,000 ESOP Options |



About Nyrada

Nyrada is developing new therapies for cardiovascular and neurological disorders, utilising novel synthetic drug compounds. Nyrada's lead programs are a cholesterol-lowering drug to prevent and treat cardiovascular disease and a treatment for brain injury which occurs following stroke or head trauma. Nyrada's commercial focus is on discovery and early phase clinical development.

For more information, please visit www.nyrada.com.

Ends

| | |
|--|---|
| Investor & Corporate Enquiries: Prue Kelly M: (+61) 0459 022 445 T: +61 2 9144 2223 E: Prue.Kelly@nyrada.com | Media queries: Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: cstrong@citadelmagnus.com |
|--|---|

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Nyrada Inc. about circumstances and events that have not yet taken place. Although Nyrada Inc. believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond Nyrada Inc.'s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Nyrada Inc. that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

Authorisation: This release was authorised by Graham Kelly (Non-Executive Director) on behalf of the Board of Directors.

Nyrada Inc., Level 4, Suite 3, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA